ConductScience.org, home

Paper41999993

From legacy to innovation: A comprehensive review of vaccine platforms against viral infections.

Farsiu N and 8 others. Virus Res, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. From legacy to innovation: A comprehensive review of vaccine platforms against viral infections. Papers, record 41999993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41999993

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
From legacy to innovation: A comprehensive review of vaccine platforms against viral infections.
PubMed
Journal
Virus Res
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Farsiu NNiloofar
2Khodadadpour Mahani FFatemeh
3Arefinia NNasir
4Charostad JJavad
5Pardeshenas MMohammad
6Mirzaei HHabibollah
7Nakhaie MMohsen
8Hassandarvish PPouya
9AbuBakar SSazaly

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Virus DiseasesMajor topic
Vaccine DevelopmentMajor topic
Viral VaccinesMajor topic
Humans
Vaccines, Virus-Like Particle
Animals
Vaccines, DNA
Vaccination
COVID-19
COVID-19 Vaccines
Vaccines, Subunit
Vaccines, Attenuated
Vaccine Efficacy

Source PubMed

Download CSV of topics

References105

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135231177Current Developments and Challenges of mRNA Vaccines.Annu Rev Biomed Eng2022https://conductscience.org/library/papers/35231177PubMed
228778817Production of virus-like particles for vaccines.N Biotechnol2017https://conductscience.org/library/papers/28778817PubMed
339772007Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions.Vaccines (Basel)2024https://conductscience.org/library/papers/39772007PubMed
431477918A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection.Nat Immunol2019https://conductscience.org/library/papers/31477918PubMed
537896820Exploring the Potential of Cytomegalovirus-Based Vectors: A Review.Viruses2023https://conductscience.org/library/papers/37896820PubMed
636184873Nanovaccines to combat virus-related diseases.Wiley Interdiscip Rev Nanomed Nanobiotechnol2023https://conductscience.org/library/papers/36184873PubMed
740896582Thermostable unit solid dose formulations for subcutaneous administration of DNA vaccines.Mol Ther Nucleic Acids2025https://conductscience.org/library/papers/40896582PubMed
837797831DNA Vaccines: History, Molecular Mechanisms and Future Perspectives.J Mol Biol2023https://conductscience.org/library/papers/37797831PubMed
938140619Evolving Horizons: Adenovirus Vectors' Timeless Influence on Cancer, Gene Therapy and Vaccines.Viruses2023https://conductscience.org/library/papers/38140619PubMed
1032392457Challenges of Making Effective Influenza Vaccines.Annu Rev Virol2020https://conductscience.org/library/papers/32392457PubMed
1137029123Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.Signal Transduct Target Ther2023https://conductscience.org/library/papers/37029123PubMed
1239433939Advanced technologies for the development of infectious disease vaccines.Nat Rev Drug Discov2024https://conductscience.org/library/papers/39433939PubMed
1340573919Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity.Vaccines (Basel)2025https://conductscience.org/library/papers/40573919PubMed
1430765167Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production.Vaccine2019https://conductscience.org/library/papers/30765167PubMed
1532407708The Challenges of Vaccine Development against a New Virus during a Pandemic.Cell Host Microbe2020https://conductscience.org/library/papers/32407708PubMed
1637168860mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV.Front Immunol2023https://conductscience.org/library/papers/37168860PubMed
1734023496Drug combination therapy for emerging viral diseases.Drug Discov Today2021https://conductscience.org/library/papers/34023496PubMed
1832514646Epstein-Barr virus-associated gastric cancer: disease that requires special approach.Gastric Cancer2020https://conductscience.org/library/papers/32514646PubMed
1932878891Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.J Virol2020https://conductscience.org/library/papers/32878891PubMed
2037632102Vaccines' New Era-RNA Vaccine.Viruses2023https://conductscience.org/library/papers/37632102PubMed

See all 105 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41999993

GET https://conductscience.org/api/papers/v1/41999993/references?page=2